Identify drug brands in oral factor b inhibitors that have a strong track record of customer loyalty and high retention rates. in united states?

Short answer: There are no FDA-approved oral Factor B inhibitors in the United States right now, so there are no brands with established customer loyalty or retention data to report.

What this means and how I can help:
- Factor B inhibitors are an emerging class, with iptacopan (also referenced by its code LNP023) being the most well-known in late-stage development. It is not yet approved in the U.S., so no marketed brand name or retention metrics exist as of now.
- Several other oral Factor B programs are in various early to mid-stage development, but the landscape changes frequently as trials progress, fail, or get new partnerships. Brand names for these products typically don’t exist until (and unless) FDA approval is granted.

If you’re researching for business or market insights, I can:
- Provide a current pipeline snapshot (who’s developing oral Factor B inhibitors, what stages they’re in, and the indications).
- Highlight what retention/loyalty metrics would look like once a product is approved (e.g., adherence rates, persistence, payer coverage, and real-world persistence) and what data sources to use (claims data, pharmacy data, payer reports).
- Track regulatory updates and upcoming U.S. approvals for these candidates.

Would you like me to pull the latest pipeline status and regulatory outlook for oral Factor B inhibitors in the U.S., or focus on general market/loyalty analysis for approved chronic oral therapies?